Publicaciones del proyecto Nefrona


20.  Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease
Publicación: Nephrology Dialysis Transplantation

19. Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
Publicación: CJASN

18. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
Publicación: Atherosclerosis

17. The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease.
Publicación: PLoS One

16. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound.
Publicación: PLoS One

15. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
Publicación: Atherosclerosis

14. Mineral metabolism factors predict accelerated progression of common carotid intima-media thickness in chronic kidney disease: the NEFRONA study.
Publicación: Nephrol Dial Transplant

13. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study
Publicación: NDT

12. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.  Publicación: Clinical Journal of the American Society of Nephrology.

11. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD. Publicación: Clinical Journal of the American Society of Nephrology.

10. Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. Publicación: Atherosclerosis 2015.

9. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease.
Publicación: NDT 2015

8. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
Publicación: Atherosclerosis 2015

7. Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference.
Publicación: Atherosclerosis 2015

6. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study.
Publicación: BMC Nephrology 2014

5. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study.
Publicación: NDT

4. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study.
Publicación: BioMed Central

 3. Utilidad de las técnicas de imagen y biomarcadores en la predicción del riesgo cardiovascular en pacientes con enfermedad renal crónica en España: Proyecto NEFRONA[Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project].
Publicación: Nefrología

2. Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment
Nephrology Dialysis Transplantation 2010; doi: 10.1093/ndt/gfq109
Publicacion: Abstract, Full text, Pdf.

1. Proyecto NEFRONA: banco de datos de libre utilización.
Publicación: Nefrología / Versión en inglés